The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi Membrane
Open accessAbstract
The host innate immune response is an important deterrent of severe viral infection in humans and animals. Nuclear import factors function as key gatekeepers that regulate the transport of innate immune regulatory cargo to the nucleus of cells to activate the antiviral response. Using severe acute respiratory syndrome coronavirus (SARS-CoV) as a model, we demonstrate that SARS-COV ORF6 protein is localized to the endoplasmic reticulum (ER)/Golgi membrane in infected cells, where it binds to and disrupts nuclear import complex formation by tethering karyopherin alpha 2 and karyopherin beta 1 to the membrane. Retention of import factors at the ER/Golgi membrane leads to a loss of STAT1 transport into the nucleus in response to interferon signaling, thus blocking the expression of STAT1-activated genes that establish an antiviral state. We mapped the region of ORF6, which binds karyopherin alpha 2, to the C terminus of ORF6 and show that mutations in the C terminus no longer bind karyopherin alpha 2 or block the nuclear import of STAT1. We also show that N-terminal deletions of karyopherin alpha 2 that no longer bind to karyopherin beta 1 still retain ORF6 binding activity but no longer block STAT1 nuclear import. Recombinant SARS-CoV lacking ORF6 did not tether karyopherin alpha 2 to the ER/Golgi membrane and allowed the import of the STAT1 complex into the nucleus. We discuss the likely implications of these data on SARS-CoV replication and pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong
Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., Ahuja, A., Yung, M. Y., Leung, C. B., To, K. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030685 · Cited by 2,628
Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus
Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R., & Tschopp, J. (2005) · Nature · doi:10.1038/nature04193 · Cited by 2,401
Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
Lau, S. K. P., Woo, P. C. Y., Li, K. S. M., Huang, Y., Tsoi, H.-W., Wong, B. H. L., Wong, S. S. Y., Leung, S.-Y., Chan, K.-H., & Yuen, K.-Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506735102 · Cited by 1,544
Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area
Booth, C. M. (2003) · JAMA · doi:10.1001/jama.289.21.joc30885 · Cited by 1,406
The Severe Acute Respiratory Syndrome
Peiris, J. S. M., Yuen, K. Y., Osterhaus, A. D. M. E., & Stöhr, K. (2003) · New England Journal of Medicine · doi:10.1056/nejmra032498 · Cited by 1,346
Li, K., Foy, E., Ferreon, J. C., Nakamura, M., Ferreon, A. C. M., Ikeda, M., Ray, S. C., Gale, M., & Lemon, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408824102 · Cited by 1,092
Donnelly, C. A., Ghani, A. C., Leung, G. M., Hedley, A. J., Fraser, C., Riley, S., Abu-Raddad, L. J., Ho, L.-M., Thach, T.-Q., Chau, P., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13410-1 · Cited by 940
Type 1 Interferons and the Virus-Host Relationship: A Lesson in Détente
García-Sastre, A., & Biron, C. A. (2006) · Science · doi:10.1126/science.1125676 · Cited by 885
Cited by
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
Coronaviruses post-SARS: update on replication and pathogenesis
Perlman, S., & Netland, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2147 · Cited by 1,764
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Randall, R. E., & Goodbourn, S. (2008) · Journal of General Virology · doi:10.1099/vir.0.83391-0 · Cited by 1,571
Coperchini, F., Chiovato, L., Croce, L., Magri, F., & Rotondi, M. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.05.003 · Cited by 1,288
“factor-3 (IRF-3), a transcription factor of the IFN genes [83,84].”
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection
Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y., & Yuen, K. Y. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-07 · Cited by 1,192
Activation and evasion of type I interferon responses by SARS-CoV-2
Lei, X., Dong, X., Ma, R., Wang, W., Xiao, X., Tian, Z., Wang, C., Wang, Y., Li, L., Ren, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17665-9 · Cited by 980
Evasion of Type I Interferon by SARS-CoV-2
Xia, H., Cao, Z., Xie, X., Zhang, X., Chen, J. Y.-C., Wang, H., Menachery, V. D., Rajsbaum, R., & Shi, P.-Y. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108234 · Cited by 957
“Our SARS-CoV-2 ORF6 results are consistent with those of previous studies showing that SARSCoV ORF6 inhibits both IFN production and STAT1 signaling by interacting with KPNA2 and altering nuclear import (Frieman et al., 2007; Kopecky-Bromberg et al., 2007).”
Resultvan Boheemen, S., de Graaf, M., Lauber, C., Bestebroer, T. M., Raj, V. S., Zaki, A. M., Osterhaus, A. D. M. E., Haagmans, B. L., Gorbalenya, A. E., Snijder, E. J., et al. (2012) · mBio · doi:10.1128/mbio.00473-12 · Cited by 914
Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
Park, A., & Iwasaki, A. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.008 · Cited by 909
Weiss, S. R., & Leibowitz, J. L. (2011) · Advances in Virus Research · doi:10.1016/b978-0-12-385885-6.00009-2 · Cited by 896
Continuous and Discontinuous RNA Synthesis in Coronaviruses
Sola, I., Almazán, F., Zúñiga, S., & Enjuanes, L. (2015) · Annual Review of Virology · doi:10.1146/annurev-virology-100114-055218 · Cited by 643
A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice
Leist, S. R., Dinnon, K. H., Schäfer, A., Tse, L. V., Okuda, K., Hou, Y. J., West, A., Edwards, C. E., Sanders, W., Fritch, E. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.050 · Cited by 613
Self-citationCrossing the Nuclear Envelope: Hierarchical Regulation of Nucleocytoplasmic Transport
Terry, L. J., Shows, E. B., & Wente, S. R. (2007) · Science · doi:10.1126/science.1142204 · Cited by 548
Host Factors in Coronavirus Replication
de Wilde, A. H., Snijder, E. J., Kikkert, M., & van Hemert, M. J. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_25 · Cited by 546
SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling
Miorin, L., Kehrer, T., Sanchez-Aparicio, M. T., Zhang, K., Cohen, P., Patel, R. S., Cupic, A., Makio, T., Mei, M., Moreno, E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016650117 · Cited by 527
The molecular virology of coronaviruses
Hartenian, E., Nandakumar, D., Lari, A., Ly, M., Tucker, J. M., & Glaunsinger, B. A. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.013930 · Cited by 525
SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists
Yuen, C.-K., Lam, J.-Y., Wong, W.-M., Mak, L.-F., Wang, X., Chu, H., Cai, J.-P., Jin, D.-Y., To, K. K.-W., Chan, J. F.-W., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1780953 · Cited by 524
Type 1 interferons as a potential treatment against COVID-19
Sallard, E., Lescure, F.-X., Yazdanpanah, Y., Mentre, F., & Peiffer-Smadja, N. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104791 · Cited by 509
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
Lokugamage, K. G., Hage, A., de Vries, M., Valero-Jimenez, A. M., Schindewolf, C., Dittmann, M., Rajsbaum, R., & Menachery, V. D. (2020) · Journal of Virology · doi:10.1128/jvi.01410-20 · Cited by 483
NS5 of Dengue Virus Mediates STAT2 Binding and Degradation
Ashour, J., Laurent-Rolle, M., Shi, P.-Y., & García-Sastre, A. (2009) · Journal of Virology · doi:10.1128/jvi.02188-08 · Cited by 451
Interplay between SARS-CoV-2 and the type I interferon response
Sa Ribero, M., Jouvenet, N., Dreux, M., & Nisole, S. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008737 · Cited by 443
“ORF6 Sequesters karyopherin alpha 2 and beta 1 Nuclear translocation of STAT1 Protein overexpression—Validated using a SARS-CoV mutant virus HEK293(T), A549, and Vero cells [36, 48]”
Accessory proteins of SARS-CoV and other coronaviruses
Liu, D. X., Fung, T. S., Chong, K. K.-L., Shukla, A., & Hilgenfeld, R. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.06.013 · Cited by 431
Antiviral activities of type I interferons to SARS-CoV-2 infection
Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S., & Huang, C. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104811 · Cited by 426
SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon
Totura, A. L., & Baric, R. S. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.04.004 · Cited by 415
Self-citationSARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway
Khan, S., Shafiei, M. S., Longoria, C., Schoggins, J. W., Savani, R. C., & Zaki, H. (2021) · eLife · doi:10.7554/elife.68563 · Cited by 398
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., O’Meara, M. J., Guo, J. Z., Swaney, D. L., Tummino, T. A., Huettenhain, R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.22.002386 · Cited by 395
Konno, Y., Kimura, I., Uriu, K., Fukushi, M., Irie, T., Koyanagi, Y., Sauter, D., Gifford, R. J., Nakagawa, S., & Sato, K. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108185 · Cited by 433
Frieman, M., Ratia, K., Johnston, R. E., Mesecar, A. D., & Baric, R. S. (2009) · Journal of Virology · doi:10.1128/jvi.02220-08 · Cited by 368
Self-citationde Wilde, A. H., Raj, V. S., Oudshoorn, D., Bestebroer, T. M., van Nieuwkoop, S., Limpens, R. W. A. L., Posthuma, C. C., van der Meer, Y., Bárcena, M., Haagmans, B. L., et al. (2013) · Journal of General Virology · doi:10.1099/vir.0.052910-0 · Cited by 348
Liang, Y., Wang, M.-L., Chien, C.-S., Yarmishyn, A. A., Yang, Y.-P., Lai, W.-Y., Luo, Y.-H., Lin, Y.-T., Chen, Y.-J., Chang, P.-C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01022 · Cited by 339
Bienvenu, L. A., Noonan, J., Wang, X., & Peter, K. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa284 · Cited by 338
Molecular pathology of emerging coronavirus infections
Gralinski, L. E., & Baric, R. S. (2015) · The Journal of Pathology · doi:10.1002/path.4454 · Cited by 319
Self-citationWyler, E., Mösbauer, K., Franke, V., Diag, A., Gottula, L. T., Arsiè, R., Klironomos, F., Koppstein, D., Hönzke, K., Ayoub, S., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102151 · Cited by 316
Deubiquitinating and Interferon Antagonism Activities of Coronavirus Papain-Like Proteases
Clementz, M. A., Chen, Z., Banach, B. S., Wang, Y., Sun, L., Ratia, K., Baez-Santos, Y. M., Wang, J., Takayama, J., Ghosh, A. K., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02406-09 · Cited by 308
Davoudi-Monfared, E., Rahmani, H., Khalili, H., Hajiabdolbaghi, M., Salehi, M., Abbasian, L., Kazemzadeh, H., & Yekaninejad, M. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-20 · Cited by 306
SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns
Redondo, N., Zaldívar-López, S., Garrido, J. J., & Montoya, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708264 · Cited by 299
Type I and III interferon responses in SARS-CoV-2 infection
Kim, Y.-M., & Shin, E.-C. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00592-0 · Cited by 296
Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response
Kindler, E., Thiel, V., & Weber, F. (2016) · Advances in Virus Research · doi:10.1016/bs.aivir.2016.08.006 · Cited by 290
An aberrant STAT pathway is central to COVID-19
Matsuyama, T., Kubli, S. P., Yoshinaga, S. K., Pfeffer, K., & Mak, T. W. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-020-00633-7 · Cited by 289
Su, Y. C. F., Anderson, D. E., Young, B. E., Linster, M., Zhu, F., Jayakumar, J., Zhuang, Y., Kalimuddin, S., Low, J. G. H., Tan, C. W., et al. (2020) · mBio · doi:10.1128/mbio.01610-20 · Cited by 288
Yang, Y., Zhang, L., Geng, H., Deng, Y., Huang, B., Guo, Y., Zhao, Z., & Tan, W. (2013) · Protein & Cell · doi:10.1007/s13238-013-3096-8 · Cited by 277
Siu, K.-L., Kok, K.-H., Ng, M.-H. J., Poon, V. K. M., Yuen, K.-Y., Zheng, B.-J., & Jin, D.-Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.008227 · Cited by 272
Evidence Supporting a Zoonotic Origin of Human Coronavirus Strain NL63
Huynh, J., Li, S., Yount, B., Smith, A., Sturges, L., Olsen, J. C., Nagel, J., Johnson, J. B., Agnihothram, S., Gates, J. E., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00906-12 · Cited by 272
Self-citationChen, X., Yang, X., Zheng, Y., Yang, Y., Xing, Y., & Chen, Z. (2014) · Protein & Cell · doi:10.1007/s13238-014-0026-3 · Cited by 272
Components and regulation of nuclear transport processes
Cautain, B., Hill, R., de Pedro, N., & Link, W. (2015) · The FEBS Journal · doi:10.1111/febs.13163 · Cited by 272
SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB
Neufeldt, C. J., Cerikan, B., Cortese, M., Frankish, J., Lee, J.-Y., Plociennikowska, A., Heigwer, F., Prasad, V., Joecks, S., Burkart, S. S., et al. (2022) · Communications Biology · doi:10.1038/s42003-021-02983-5 · Cited by 272
Wu, J., Shi, Y., Pan, X., Wu, S., Hou, R., Zhang, Y., Zhong, T., Tang, H., Du, W., Wang, L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108761 · Cited by 265
Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice
Becker, M. M., Graham, R. L., Donaldson, E. F., Rockx, B., Sims, A. C., Sheahan, T., Pickles, R. J., Corti, D., Johnston, R. E., Baric, R. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808116105 · Cited by 264
Self-citationViral tricks to grid-lock the type I interferon system
Versteeg, G. A., & García-Sastre, A. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.05.009 · Cited by 256
Lamers, M. M., van der Vaart, J., Knoops, K., Riesebosch, S., Breugem, T. I., Mykytyn, A. Z., Beumer, J., Schipper, D., Bezstarosti, K., Koopman, C. D., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020105912 · Cited by 227
Computational analysis of microRNA-mediated interactions in SARS-CoV-2 infection
Saçar Demirci, M. D., & Adan, A. (2020) · PeerJ · doi:10.7717/peerj.9369 · Cited by 190
“ORF6 gene size: 186 hsa miRNAs: 1 hsa-miR-190a-5p Blocking nuclear import of STAT1 by binding to nuclear imports (Frieman et al., 2007)”
BackgroundFrieman, M. B., Chen, J., Morrison, T. E., Whitmore, A., Funkhouser, W., Ward, J. M., Lamirande, E. W., Roberts, A., Heise, M., Subbarao, K., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000849 · Cited by 158
“SARS-CoV ORF6 blocks STAT1 nuclear import[18], PLP blocks IRF3 activation[51], NSP7[51], NSP15[51], ORF3b and N have been shown to be IFN antagonists as well[19].”
BackgroundSelf-citationGheibi (2021) · doi:10.4103/1995-7645.318304 · Cited by 80
Joubert, D. A., Blasdell, K. R., Audsley, M. D., Trinidad, L., Monaghan, P., Dave, K. A., Lieu, K. G., Amos-Ritchie, R., Jans, D. A., Moseley, G. W., et al. (2014) · Journal of Virology · doi:10.1128/jvi.01812-13 · Cited by 50
Metadata
- Authors
- Frieman, M., Yount, B., Heise, M., Kopecky-Bromberg, S. A., Palese, P., & Baric, R. S.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2007-09-15
- Volume
- 81
- Issue
- 18
- Pages
- 9812-9824
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2153593258
- Cited by
- 507
- References
- 59
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.